← Back to Search

Donor Matching Strategies for Blood Cancer Transplants (BMT CTN 1702 Trial)

N/A

Waitlist Available

Research Sponsored by Center for International Blood and Marrow Transplant Research

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified

Signed informed consent, and assent if applicable. Consent may be signed prior to completion of family typing but patients will only be considered evaluable upon confirmation that there is no suitable HLA-identical or 1 allele or antigen mismatched related donor available

Must not have

Prior allogeneic HCT (prior autologous transplant is allowed)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will compare two ways of finding a donor for a person with blood cancer who needs a transplant.

Who is the study for?

This trial is for patients with conditions like various leukemias, lymphomas, sickle cell disease, and aplastic anemia who need a stem cell transplant but don't have a closely matched family donor. They should be fit for transplantation based on their medical history and tests. Patients already having had an allogeneic transplant can't join.

What is being tested?

The study aims to see if searching for a fully matched unrelated donor before considering alternative donors leads to better survival within two years after joining the study compared to going straight to an alternative donor transplant.

What are the potential side effects?

While specific side effects are not listed here, allogeneic transplants typically carry risks such as graft-versus-host disease (where the new cells attack your body), infections due to weakened immune system, organ damage, and reactions from the conditioning regimen.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I plan to have a stem cell transplant from a donor within 6 months if we find a match.

Select...

I have signed the consent form and understand the study.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have not had a transplant from another person.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Overall Survival for MUD Very Likely and MUD Very Unlikely Arms

Secondary study objectives

Barriers to Transplant

Cumulative Incidence of Transplant by Donor Search Prognosis Score

Other study objectives

AML or ALL in first complete remission or early stage MDS Substudy - CRFS

Muscular Dystrophy

AML or ALL in first complete remission or early stage MDS Substudy - QoL

+15 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: Donor Search Prognosis: MUD Very UnlikelyExperimental Treatment1 Intervention

Patients who are Very Unlikely to find a MUD, defined as having a \<10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.

Group II: Donor Search Prognosis: MUD Very LikelyExperimental Treatment1 Intervention

Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a \>90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.

Group III: Donor Search Prognosis: MUD Less LikelyExperimental Treatment1 Intervention

Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.

0 / 3Eligibility criteria met